Hypertension and nephrology

[Changing dietary guidelines in obesity. MOMOT recommendation]


DECEMBER 20, 2014

Hypertension and nephrology - 2014;18(05-06)

[In the 70s and 80s due to the heart attack „epidemic” the low fat diet was encouraged based on the cholesterol theory, with moderate success. At the same time, the consumption of carbohydrates increased with the frequency of obesity rising from 1971 to 30% in the USA. Foods with high glicemic index and rich in carbohydrates result in a fast increase in glucose level, insuline actions also leading to glucose – fatty acid transformation and weight gain. Over the last decades several comparative trials have proven that with the low carb diet one can lose about 3- more than with the low fat diet in half a year. The excessive low carbohydrate Atkins diet over 1 year (), was superior even to ZONE (), LEARN (), ORNISH () diet, in another trial, over two years also the „low fat” diet. International Association for the Study of Obesity (IASO) recommends an increased protein intake (15 → 25%) along with carbohydrate with low glicemic index (GI). According to the summarized guidelines of the Hungarian Society of Obesitology and Excercise Therapy (MOMOT) low calorie (1200-1500 kcal / day), low-carb (<45%) – low-GI, high-protein (≥ 25%), low-fat (38→30%) diet is recommended, by witch a weight loss of 10 kg/half year can be expected. After half a year patient compliance deteriorates and they can hardly keep even the low-carb diet, whose significant advantage diminishes by this. We hope that patient compliance can be helped with two new appetite decreasing drugs, namely lorcaserin and a combination of phentermin and topiramat. Future dietary recommendations may be influenced by the new guideline issued in November 2013 by AHA/ACC, and the Obesity Society the final approval of which by NHLBI can be expected by June 2014.]


  1. Szent Imre Egyetemi Oktatókórház, Budapest



Further articles in this publication

Hypertension and nephrology

[Neprilysin Inhibition: a Prospective New Clinical Therapeutic Group in Heart Failure? – The PARADIGM-HF Study]


Hypertension and nephrology

[Genetic diagnostics of the trombosis risk]

SZOKOLAI Viola, HARSÁNYI Gergely, VÉGH Csaba, ELBERT Gábor, TÚRI Sándor, NAGY Zsolt B.

[The cardiovascular system and the coalugation process play essential role in regulating the homestasis of the human body. Thrombuses may appear in veins (venous thrombosis) as well as arteries (arterial thrombosis) that may cause a wide range of ischemic vascular diseases. By mapping genetic risk factors that may accelarate the development of thrombosis, the quality of medical preventions and therapies can be improved. The most frequent gene mutations (FII, FV, PAI-1, MTHFR and EPCR gene polimorphisms) can be tested by methods based on PCR, real-time PCR and macroarray techniques. Professionals may use genetic results for selecting appropriate and optimal therapies based on the context of a patient’s medical history.]

Hypertension and nephrology

[Article Reports]

Hypertension and nephrology

[Renal Denervation: an Invasive Treatment Option in the Treatment of Resistant Hypertension]


Hypertension and nephrology

[Report on the 31st General Assembly of the Hungarian Society of Nephrology]

DEÁK György

All articles in the issue

Related contents

Lege Artis Medicinae



[This paper reviews the current knowledge on the association of obesity and gastrointestinal disorders. While the relationship between obesity and cardiovascular disorders has recently gained wide professional publicity, there are few data on the gastroenterological aspects of obesity. After a discussion on obesity as an epidemic, its international and national prevalence, and public health risks, the most common obesity-related gastrointestinal disorders, their incidence, pathomechanism and consequences are presented by the organ systems affected, including gastrooesophageal reflux disease, fatty liver, gallstone disease, diseases of the pancreas, and colorectal carcinoma. Finally, the means of prevention and treatment are summarized.]

Hypertension and nephrology

[Association of body composition and mortality in patients on maintenance dialysis and on waitlist and after kidney transplantation]


[Overweight [body mass index (BMI) = 25-30 kg/m2] and obesity (BMI ≥30 kg/m2) are epidemic in both developed and developing countries. Obesity has been recognized as risk factor for the development and progression of chronic kidney disease and is associated with increased cardiovascular risk and poor survival. Almost 2/3 of maintenance hemodialysis patients die within five years of commencing dialysis treatment. Although patients on the waitlist having less severe comorbidities than their non-listed counterparts, the death rate remains high while it can take years for an organ donation. In patients with end stage renal disease (ESRD) undergoing maintenance hemodialysis an “obesity paradox” has been consistently reported, i.e., a high BMI is incrementally associated with better survival. Overweight and obesity are highly prevalent in patients at the time of kidney transplantation. Indeed, most transplant centers in US may suspend wait-listing of obese patients with a BMI above 30 or 35 kg/m2 and refer them for weight reduction procedures such as bariatric surgery as a contingency for the transplant surgery. The effect of pre- and post-transplant obesity in kidney transplanted patients on long-term graft and patient survival has not been well established. We have reviewed and summarized salient recent data pertaining to body composition and clinical outcomes about the association of survival and body composition in transplant-waitlisted dialysis patients and kidney transplanted recipients. ]

LAM Extra for General Practicioners

[The possibilities of pharmacological treatment of obesity]

PADOS Gyula, SIMONYI Gábor, BEDROS J. Róbert

[There have been attempts to treat obesity with medicines for nearly 100 years, since the discovery of ephedrine. For decades amphetamine derivates and agents stimulating or inhibiting the release of noradrenaline and dopamine have been applied. However, most of theses drugs had to be gradually withdrawn, due to their adverse effects on the cardiovascular and central nervous system or their sympaticotonic effect. Dexfenfluramine (Isolipan), which was introduced in the 90s, did not have such side effects, but it turned out to potentially cause valvular heart disease. Finally, sibutramin (Reductil) was introduced, which again had to be withdrawn in 2010 due to its hypertensive and cardiovascular side effects. After all, we were left without any appetite-suppressant drugs. Orlistat therapy, (Xenical 120 mg, alli 60 mg - OTC), which inhibits the absorption of fat, can eliminate only 30% of the consumed food's fat content, at the price of gastrointestinal side effects. The latest result of research carried out wordwide is that in 2012 the FDA approved commercial distribution of the selective 5HT2/c serotonin agonist lorcaserin (Belviq), which enhances satiety, in the USA. Unfortunately, in 2013 the EMEA temporarily postponed the lauch of this drug, until certain adverse effects are excluded. For diabetic patients, the GLP-1 agonist exenatid and the GLP-analog liraglutid, which can also reduce body weight, are available in the form of injections. ]

Lege Artis Medicinae

[Mazes and compass in prognostic value of cardiovascular risk factors]

KÉKES Ede, KISS István

[The risk assessment of cardiovascular disease is dispensable in everyday practice, because this disease-group gives the high-est death rates all over the world - in developed countries, in Central European Region, including Hungary. Based on reliable surveys world side, we need in addition to coronary heart disease, stroke has been reckoned today to peripheral vascular disease, type-2 diabetes, and chronic kidney diseases as well. It seems useful to the new name i.e., atherosclerotic cardiovascular diseases. It stands as smoking, hypertension, dyslipidemia risk factors among this group of diseases in the background, but more and more importance is given to visceral obesity, physical inactivity, alcohol consumption and psycho-social status. It has to count with the fact that the individual factors together and appear further worsen to mortality rate. The greatest interference arises because the cardiovascular risk estimation proposed by embodiments of non-uniform principles. Undoubtedly, the resolution of ACC/AHA 2010 was the first correct compass, because the classification and utility values of the factors precisely regulated. But in addition, it is essential that in the risk assessment not only the “global estimation” (tables, other forms) will be conducted, but also other important parameters characterizing the extended factors (vascular structure, obesity, psycho-social status, etc.) - set schedule and regulations - acting on to be carried out. We presented in cardiovascular risk assessment methodology and the most profitable methods of estimation based on the preventive guidelines, extern opinions generally accepted now and own experiences. We propose to modify the risk assessment me-thod.]

Lege Artis Medicinae

[The role of neurohormonal regulation in the development of insulin resistance in chronic stress]


[The effects of the chronic stress could not be avoided recently. The pathognomic regulation of the neurohormonal events is responsible for the manifestation of diseases such as obesity, cardiovascular diseases, diabetes mellitus type 2, depression, tumors, inflammations, allergy. Two major regulatory systems are involved in the neuroendocrine alterations caused by stress: the hypothalamus-pituitary-adrenal (HPA) axis and the sympathetic nervous systems. The chronic activation of the adrenocortical system leads to insulin resistance and obesity associating with vascular, arteriosclerotic and inflammatory symptoms. The revealing of the pathognomic events on time and the enhanced physical activity may provide the effective prevention of these frequent diseases.]